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INTRODUCTION
The accurate assessment of renal function is essential for imple-
menting safe chemotherapy among patients with malignancies
(1-3). Glomerular filtration rate (GFR) in the Japanese clinical
setting has commonly been estimated as 24-h creatinine clearance
(CCr), although the gold standard is inulin clearance (CIn).
Equations for estimated GFR based on creatinine (Cr-eGFR) and
cystatin C (CysC-eGFR) were established for Japanese children
during 2013 (4) and 2014 (5), respectively. The Cr-eGFR has been
recommended for pediatric patients with chronic kidney disease
(CKD), but CysC-eGFR should be used for patients with abnormal
muscle mass because muscle mass affects serum creatinine levels.
In pediatric patients with malignancies and lower muscle mass
than healthy children, Cr-eGFR can overestimate their renal func-
tion and result in an overdose of chemotherapeutic agents (6). On
the other hand, thyroid dysfunction (7), human immunodeficiency
virus (HIV) infection (8), and medication with steroids or immuno-
suppressive agents can affect serum cystatin C (CysC) values (9-
11). Therefore, CysC-eGFR is not recommended for such patients.
CysC is associated with the pathology of metastatic and invasive
cancer (12-15). We aimed to define the applicability of CysC-eGFR
by investigating factors other than renal function that affect
serum CysC levels in pediatric patients with malignancies.
MATERIALS AND METHODS
The study population comprised 13 patients aged up to 17 years
with malignancies who underwent chemotherapy and simultane-
ous measurements of their CCr and serum CysC values at our
hospital between January 2013 and February 2015. Information
about the patients retrospectively collected from their clinical re-
cords included age, weight, height, body surface area (BSA),
serum creatinine, urinary creatinine, urine volume, serum CysC,
white blood cell count (WBC), absolute neutrophil count (ANC),
serum C reactive protein (CRP), free-thyroxine (fT4), disease di-
agnosis, tumor activity (without therapy, complete [CR] or partial
[PR] response, stable [SD] or progressive [PD] disease), duration
between the day of starting chemotherapy and the test day, medica-
tion with granulocyte-colony stimulating factor (G-CSF), steroid,
and levothyroxine on the test day, and steroid dose. We classified
the solid tumor activity according to the response evaluation
criteria in solid tumors (RECIST) guidelines (16). Table 1 defines
the criteria for CR, PR, SD and PD. Patients with complete remis-
sion of hematological malignancies such as acute leukemia and
lymphoma after induction chemotherapy were classified as having
achieved CR. Complete remission was defined as5% blasts in
bone marrow and the absence of extramedullary disease in pa-
tients with acute leukemia, and the absence of residual tumor and
extranodal disease in patients with lymphoma. The Ethics Com-
mittee at Tokushima University Hospital approved the study (Ap-
proval number : 2398).
Urine was collected for two or three consecutive days. Results
were excluded when failure to complete urine collection was docu-
mented in the clinical record. Both serum and urinary creatinine
values were measured in-house using an automatic analyzer
(Hitachi Ltd., Tokyo, Japan) with enzymatic assays (Shino-Test
Corporation, Kanagawa, Japan). Levels of serum CysC were meas-
ured using a colloidal gold immunoassay (Alfresa Pharma Corpo-
ration, Osaka, Japan) at SRL Inc. (Tokyo, Japan), which was cali-
brated to the standardized value to ERM-DA472/IFCC. The refer-
ence serum CysC values were those published in the Chronic
Kidney Disease (CKD) guidelines 2012 (17) for patients aged16
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years (Table 2), and values established by SRL Inc. for patients
aged 17 years (male and female, 0.630.95 and 0.560.87 mg/L,
respectively).
The CysC-eGFR was calculated using the formula 104.1 × 1/
CysC (mg/L) - 7.80 (mL/min/1.73 m2), which was determined by
measuring CIn in pediatric CKD patients between the ages of 1
month and 18 years (5). Correlations between CCr and CysC-
eGFR were analyzed.
We focused on factors that might influence serum CysC levels,
and divided the patients into paired groups according to tumor
activity (without therapy or with SD or PD vs. with CR or PR) ; cell
recovery phase after chemotherapy (duration between the day on
which chemotherapy was started and the test day14 vs. 14
days) ; neutropenic phase (ANC1000 vs.1000/μL) ; inflamma-
tion response (CRP0.3 vs.0.3 mg/dL) ; and medication with or
without G-CSF, steroid, and levothyroxine. We compared the fre-
quency of serum CysC above or below reference values between
each pair of groups.
Normal distribution was assessed using Kolmogorov-Smirnov
tests. Descriptive statistics for continuous variables are presented as
meanstandard deviation (SD), except for age, which is pre-
sented as median and range. This is because the distribution of age
was not normal. Categorical variables are presented as frequencies
(%) with 95% confidence intervals (CI). Differences in mean values
between the two groups were analyzed using t tests or Welch tests,
followed by F tests. Differences in frequencies between groups
were analyzed using Fisher exact tests. Correlations were analyzed
using Pearson correlation coefficients. Values of p0.05 were
considered to indicate statistically significant differences. All data
were statistically analyzed using EZR (Saitama Medical Center,
Jichi Medical University).
RESULTS
We collected information from seven male and six female pa-
tients at 19 and 17 time points, respectively. Patients were diag-
nosed with intracranial germ cell tumors (n = 3) ; malignant periph-
eral nerve sheath tumor with neurofibromatosis type 1 (n = 2) ; and
acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma
(NHL), testicular germ cell tumor, rhabdomyosarcoma, osteosar-
coma, Wilms tumor, neuroblastoma, and malignant glioblastoma
(n = 1 each).
The median age at the time of the test was 4 (range ; 117)
years. The mean CCr was 140.928.6 mL/min/1.73 m2. CCr
data collected at only one time point was below the reference
value of 90 mL/min/1.73 m2 (89.1 mL/min/1.73 m2 ; 2.8% ; 95% CI,
0.1%14.5%) and CCr data at all other time points were above the
reference values. With respect to serum CysC, values at four time
points (11.1% ; 95% CI, 3.1%26.1%) and five time points (13.9% ;
95% CI 4.7%29.5%) were above and below the reference values,
respectively. The correlation coefficient between CCr and CysC-
eGFR was 0.405 (p = 0.014).
Values for serum CysC were above the reference values in four
patients at four time points, and below the reference value at five of
six time points in a female patient who was undergoing chemother-
apy for intermediate risk Stage 3 neuroblastoma diagnosed by bi-
opsy before starting therapy. The tumor did not completely disap-
pear after eight cycles of chemotherapy. The residual tumor com-
prised an area of calcification and some ganglioneuroma or gan-
glioneuroblastoma at the end of the chemotherapy treatment. We
excluded the data from this patient from further analysis as we
considered that unique personal factors influenced her serum
CysC levels.
We analyzed risk factors associated with elevated serum CysC
levels other than renal function among data derived at 30 time
points from 12 patients (male, 19 time points ; female, 11 time
points). The median age at the time of the test was 8.5 (range ; 1
17) years. The mean CCr was 137.627.5 mL/min/1.73 m2. Infor-
mation about levothyroxine medication was obtained at five time
points from a patient with pituitary hypothyroidism whose fT4
levels were normalized by hormone replacement therapy. Informa-
tion about steroid medication was obtained at seven time points
from three patients. Information about medication with therapeutic
doses of prednisolone was obtained at one time point each from one
patient with ALL and from another with NHL. Information about
medication with maintenance doses of hydrocortisone as hormone
replacement therapy for a patient with pituitary adrenocortical in-
sufficiency was obtained at five time points.
Values for serum CysC at four time points were above the refer-
ence values (13.3%, 95% CI, 3.8%30.7%). The correlation coeffi-
cient between CCr and CysC-eGFR was 0.355 (p= 0.0544). Mean
CCr did not significantly differ between groups with elevated and
normal serum CysC values (127.019.5 vs. 139.228.5 mL/min/
1.73 m2 ; p = 0.415). Therefore, we considered that factors other
than renal function influenced serum CysC in group with elevated
serum CysC values.
Table 3 shows the results of comparisons of the frequency of
elevated serum CysC levels between groups divided according to
restrictive risk factors. The frequency of elevated serum CysC was
Table 1. Definitions for tumor activity classification
Definition
Complete response Disappearance of all target lesions and normaliza-
tion of tumor maker level
Partial response At least a 30% decrease compared with baseline
sum of longest diameter of target lesions, and/or
tumor marker level maintained above normal limit
Stable disease Neither sufficient shrinkage to qualify as partial
response nor sufficient increase to qualify as pro-
gressive disease, compared with smallest sum of
longest diameter of target lesions since treatment
started
Progressive disease At least a 20% increase compared with smallest
sum of longest diameter of target lesions since
treatment started or emergence of one or more
new lesions








35 months 0.88 1.06 1.26
611 months 0.72 0.98 1.25
1217 months 0.72 0.91 1.14
1823 months 0.71 0.85 1.04
211 years 0.61 0.78 0.95
1214 years Male 0.71 0.86 1.04
Female 0.61 0.74 0.91
1516 years Male 0.53 0.75 0.92
Female 0.46 0.61 0.85
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statistically higher in a group without therapy or with SD or PD
than in a group that achieved CR or PR (44.9% vs. 0.0% ; p = 0.0046).
The correlation between CCr and CysC-eGFR in a group without
therapy or with SD or PD was expressed by the equation ; CysC-
eGFR = -0.1639 × CCr + 135.29, with a correlation coefficient of -
0.345 (p = 0.3633). The correlation between CCr and CysC-eGFR in
a group with CR or PR was expressed by the equation ; CysC-
eGFR = 0.3745 × CCr + 73.096, with a correlation coefficient of
0.663 (p = 0.0011) (Figure 1).
DISCUSSION
Cystatin C is a 13-kDa low-molecular -weight protein compris-
ing 120 amino acids. Almost all human nuclear cells produce
CysC at a constant rate and release it into the bloodstream. Serum
CysC levels have served as an endogenous GFR marker, like
serum creatinine, because it is reabsorbed and catabolized by kid-
ney tubules and is not returned to blood after free infiltration of
the glomeruli (18, 19).
Because serum CysC values are not influenced by muscle mass,
unlike creatinine (20), CysC-eGFR rather than Cr-eGFR is recom-
mended for assessments of renal function among patients with ab-
normal muscle mass than healthy matched controls. We reported
that Cr-eGFR can overestimate the renal function of Japanese
pediatric patients undergoing chemotherapy as they have less
muscle mass than healthy children (6). Several reports suggest
that CysC is more appropriate than creatinine for evaluating renal
function in pediatric patients with malignancies (21, 22).
However, with thyroid dysfunction (7), HIV (8), and medication
with steroids or immunosuppressive agents can alter serum CysC
levels (9-11). Moreover, CysC is an inhibitor of cysteine proteases,
such as cathepsin, which might be associated with the metastasis
and invasion of tumor cells (23). Studies of patients with several
types of malignant tumors have found elevated serum CysC levels
regardless of renal function (12-15).
We found a low correlation coefficient between CCr and CysC-
eGFR in pediatric patients with malignancies. Although no CCr
data collected at 36 time points indicated deteriorated renal func-
tion, serum CysC levels were above and below the reference
values at four and five time points, respectively. Therefore, we
considered that factors other than renal function influence serum
CysC. Serum CysC values were below the reference at five of six
time points from a female patient with intermediate risk Stage 3
neuroblastoma. We considered that this was caused by factors
specific to this patient. Tumor cells generally tend to quickly grow
and divide, and therefore chemotherapeutic agents can inhibit cell
division and induce tumor regression. However, the histological
response of intermediate risk Stage 3 neuroblastoma cells to che-
motherapy sometimes indicated maturation (24). Her neuroblas-
toma cells had also differentiated into ganglioneuroma or gan-
glioneuroblastoma after chemotherapy. The ability of tumor cells
to differentiate might affect serum CysC levels. Further studies
should evaluate serum CysC levels in patients with malignancies
that undergo maturation after chemotherapy. In the present study,
we excluded her findings from further analysis and investigated
analyzed factors that might be associated with elevated serum
CysC levels other than the deterioration of renal function in the
clinical setting of malignancy based on the remaining data derived
from 30 time points.
We compared the frequency of elevated serum CysC levels
among the risk factors of tumor activity, cell recovery phase after
chemotherapy, neutropenic phase, inflammation response, and
medication with G-CSF, steroid, or levothyroxine. Only tumor
activity was statistically associated with elevated serum CysC val-
ues. Levels of serum CysC were elevated in data collected at four of
nine time points before treatment or at the stage of SD or PD. On
the other hand, data collected at all 21 time points at the CR or PR
Table 3. Comparison of frequency of elevated serum cystatin C
values
Risk factors Elevated CysC Normal CysC P
Tumor activity
Without therapy or SD or PD 4 5 0.0046
With CR or PR 0 21
Cell recovery phase after chemotherapy (N=20)
14 days 0 13 1
14 days 0 7
Neutropenic phase
ANC1000/μL 4 14 0.13
ANC1000/μL 0 12
Inflammation response
CRP0.3 mg/dL 1 2 0.36
CRP0.3 mg/dL 3 24
G-CSF medication
With 0 7 0.548
Without 4 19
Steroid medication
With 1 6 1
Without 3 20
Levothyroxine medication
With 1 4 0.538
Without 3 22
CysC cystatin C, SD stable disease, PD progressive disease, CR complete
response, PR partial response, ANC absolute neutrophil count, CRP se-
rum C reactive protein, G-CSF granulocyte -colony stimulating factor
Comparisons were analyzed using Fisher exact test
Figure 1. Scatter plot of CCr and CysC-eGFR in a group without
therapy or with SD or PD (circles) and a group with CR or PR (squares).
Solid and broken line shows relationships between CCr and CysC-
eGFR in a group without therapy or with SD or PD and a group with
CR or PR, respectively.
The Journal of Medical Investigation Vol. 65 August 2018 233
stage revealed normal serum CysC levels, suggesting that serum
CysC can become elevated during active tumor-cell proliferation.
Moreover, the correlation coefficient between CCr and CysC-
eGFR improved to 0.663 (p = 0.0011) when data from only 21 time
points obtained at the time of CR or PR were analyzed.
The relationship between steroidal therapy and serum CysC has
been discussed (9-11). The present study found that steroid
medication was not a risk factor for influencing serum CysC levels.
Various doses of steroids are often administered for various rea-
sons in the clinical setting of malignancy, such as tumor reduction,
decompression of intracranial pressure, and hormone replace-
ment for hypopituitarism. The influence of steroids on serum CysC
levels should be separately assessed in a future study.
The present study has some limitations. Firstly, we adopted CCr
as the measurement of the GFR. Generally, the CCr estimates
higher than the true GFR compared with the CIn, because of
tubular creatinine secretion. If a more reliable measurement of
GFR, such as CIn, had been adopted in the present study, the rela-
tionship between measured GFR and CysC-eGFR might have
been clearer. Secondly, the equation of CysC-eGFR for Japanese
children was developed based on CIn in pediatric patients with
CKD. No findings in the present study indicated obvious renal
dysfunction, and the mean CCr was 140.928.6 mL/min/1.73 m2.
However, the median maximum CIn collected from CKD patients
to develop the equation of CysC-eGFR for Japanese children was
71.0 (interquartile range ; 52.997.2) mL/min/1.73 m2. The CysC-
eGFR equation for Japanese children has not yet been validated
among children in general. Sharma AP et al. (25) concluded that
the diagnostic accuracy of several CysC-eGFR equations for
Europeans and Canadian children, such as the equations of
Bökenkamp, Filler, Grub, and Zapitelli, varied at different GFR.
The equation of CysC-eGFR for Japanese children might also have
been inaccurate due to variations in GFR.
CONCLUSIONS
Levels of serum CysC can fluctuate regardless of renal function.
In pediatric patients with malignancies, serum CysC levels might
become elevated, and CysC-eGFR might become unpredictable
during the active phase of tumors.
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